Skip to main content

Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants

Recruiting · Phase 3 · NCT06575192

Conditions: Breast Reconstruction

At a glance

Research payments reported, 2025
$631,071
U.S. investigators named
19
Sites paid
20
Planned or actual enrollment
264

About the trial

Sponsor
AbbVie
Tested
ARTIA Reconstructive Tissue Matrix (device)
Dates
Started 2024-11-05; completion 2031-02
Results posted
Not yet

The purpose of this study is to evaluate the safety and effectiveness of ARTIA in adult participants undergoing immediate, two-stage, implant-based breast reconstruction post-mastectomy.

From ClinicalTrials.gov, last updated 2026-08-06. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $631,071 in research payments for this study in 2025 (66 payments).

Products named: Artia

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.